KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Debt to Equity (2016 - 2025)

Pfizer (PFE) has disclosed Debt to Equity for 17 consecutive years, with $0.65 as the latest value for Q2 2025.

  • On a quarterly basis, Debt to Equity fell 1.17% to $0.65 in Q2 2025 year-over-year; TTM through Jun 2025 was $0.65, a 1.17% decrease, with the full-year FY2024 number at $0.65, down 19.73% from a year prior.
  • Debt to Equity was $0.65 for Q2 2025 at Pfizer, down from $0.69 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.81 in Q4 2023 to a low of $0.35 in Q2 2023.
  • A 5-year average of $0.56 and a median of $0.57 in 2023 define the central range for Debt to Equity.
  • Peak YoY movement for Debt to Equity: tumbled 50.5% in 2021, then soared 115.54% in 2023.
  • Pfizer's Debt to Equity stood at $0.5 in 2021, then decreased by 24.72% to $0.37 in 2022, then skyrocketed by 115.54% to $0.81 in 2023, then decreased by 19.73% to $0.65 in 2024, then decreased by 0.04% to $0.65 in 2025.
  • Per Business Quant, the three most recent readings for PFE's Debt to Equity are $0.65 (Q2 2025), $0.69 (Q1 2025), and $0.65 (Q4 2024).